Meeting
2023 ASCO Gastrointestinal Cancers Symposium
An adaptive approach to neoadjuvant therapy to maximize resection rates for pancreatic adenocarcinoma: A phase II trial.
Authors
Davendra Sohal
University of Cincinnati, Cincinnati, OH;
Davendra Sohal , Jordan Kharofa , Olugbenga Olanrele Olowokure , Adam Rojan , Sameer H. Patel , Gregory C. Wilson , Jeffrey J. Sussman , Katie Moreland , Krushna Patra , Vladimir Bogdanov , Taylor S Riall , Yana Zavros , Rachna T. Shroff , Syed A. Ahmad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04594772
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS771)
DOI
10.1200/JCO.2023.41.4_suppl.TPS771
Abstract #
TPS771
Poster Bd #
Q7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2020 Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of Nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study) (NCT03483038).
First Author: Hiral D. Parekh